<DOC>
	<DOCNO>NCT00324831</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cyclophosphamide , doxorubicin , vincristine , prednisone , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Colony-stimulating factor , GM-CSF , may increase number immune cell find bone marrow peripheral blood may help immune system recover side effect chemotherapy . Vaccines make person 's cancer cell may help body build effective immune response kill cancer cell . It yet know whether give GM-CSF together vaccine therapy effective give GM-CSF together placebo give combination chemotherapy rituximab treat diffuse large B-cell lymphoma . PURPOSE : This randomized phase III trial study GM-CSF vaccine therapy see well work compare GM-CSF placebo give combination chemotherapy rituximab first-line therapy treat patient stage II , stage III , stage IV diffuse large B-cell lymphoma .</brief_summary>
	<brief_title>GM-CSF With Without Vaccine Therapy After Combination Chemotherapy Rituximab First-Line Therapy Treating Patients With Stage II , Stage III , Stage IV Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare 3-year disease-free survival patient high-intermediate- high-risk bulky stage II stage III IV diffuse large B-cell lymphoma treat sargramostim ( GM-CSF ) without autologous immunoglobulin idiotype-KLH conjugate vaccine ( FavId® ) combination chemotherapy comprise cyclophosphamide , doxorubicin , vincristine , prednisone , rituximab ( CHOP-R ) . Secondary - Compare 2-year disease-free survival , duration response , time progression , overall survival , safety patient treat regimen . - Estimate rate immune reactivity FavId® . OUTLINE : This randomize , double-blind , placebo-controlled study . Patients stratify accord risk score ( 3 [ high-intermediate ] v 4 5 [ high ] ) . - Chemotherapy : Patients receive cyclophosphamide IV , doxorubicin hydrochloride IV , vincristine IV , rituximab IV day 1 oral prednisone day 1-5 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . - Sargramostim ( GM-CSF ) without autologous immunoglobulin idiotype-KLH conjugate vaccine ( FavId® ) : Patients achieve complete remission ( CR ) unconfirmed CR chemotherapy FavId® available randomize 1 2 treatment arm . - Arm I : Patients receive FavId® vaccine subcutaneously ( SC ) day 1 . Patients also receive sargramostim ( GM-CSF ) SC day 1-4 . - Arm II : Patients receive placebo SC day 1 GM-CSF SC arm I . In arm , treatment repeat month 6 month every 2 month 24 month ( 18 total vaccination ) absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 2 year . PROJECTED ACCRUAL : A total 480 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Idiotypes</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diffuse large Bcell lymphoma Bulky stage II stage III IV disease Treatment naïve International Prognostic Index score 3 ( highintermediate ) 4/5 ( high ) Lymphoma accessible sample exist biopsy material judge suitable preparation autologous immunoglobulin idiotypeKLH conjugate vaccine ( FavId® ) No history CNS lymphoma meningeal lymphomatosis No history indolent lymphoma PATIENT CHARACTERISTICS : ECOG performance status 02 Platelet count &gt; 75,000/mm^3 ALT AST &lt; 2 time upper limit normal Not pregnant nursing No history unresolved hepatitis B viral infection No history treat prior malignancy unless remission ≥ 2 year , except treat nonmelanoma carcinoma skin situ cervical carcinoma prostatic carcinoma No contraindication doxorubicin hydrochloride ( e.g. , abnormal contractility ECG ) No contraindication vincristine ( e.g. , peripheral neuropathy ) No know HIV positivity No serious nonmalignant disease , include follow : Psychiatric disorder Compromised pulmonary function Congestive heart failure Active bacterial , viral , fungal infection PRIOR CONCURRENT THERAPY : No prior keyhole limpet hemocyanin No plan radiotherapy study therapy No concurrent systemic immunosuppressive therapy ( e.g. , steroid )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
</DOC>